Synapse - Works

Results (5599)

Aberrant cell cycle programming confers rapid lethality in the EUSOX11+ CCND1 MCL mouse model

Meeting Abstract

Edwards, D. R.; Kuo, P. Y.; Lagana, A.; Park, S.; Nedumaran, P.; Leshchenko, V.; Christie, S.; Jatiani, S.; Teruya-Feldstein, J.; Parekh, S.
Blood (2020)

Fulltext@MSK | Save

Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study

Meeting Abstract

Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
Blood (2020)

Fulltext@MSK | Save

Impact of additional cytogenetic abnormalities and complex karyotype on event-free survival in acute promyelocytic leukemia: Analysis from a single academic center plus the APML4 study

Meeting Abstract

Epstein-Peterson, Z. D.; Rajeeve, S.; Derkach, A.; Park, J. H.; Stein, E. M.; Zhang, Y.; Iland, H. J.; Tallman, M. S.
Blood (2020)

Fulltext@MSK | Save

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: Updated efficacy and safety results of the phase 3 CANDOR study

Meeting Abstract

Dimopoulos, M. A.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D. S.; Weisel, K.; Gavriatopoulou, M.; Oriol, A.; Rabin, N. K.; more...
Blood (2020)

Fulltext@MSK | Save

Increased interleukin-8 (IL8)-CXCR2 signaling promotes progression of bone marrow fibrosis in myeloproliferative neoplasms

Meeting Abstract

Dunbar, A.; Lu, M.; Farina, M.; Park, Y.; Yang, J.; Kim, D.; Karzai, A.; Salama, M. E.; Snyder, J.; Krishnan, A.; more...
Blood (2020)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
Blood (2020)

Fulltext@MSK | Save

Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Meeting Abstract

Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
Blood (2020)

Fulltext@MSK | Save

KarMMa-3: A phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma

Meeting Abstract

Delforge, M.; Baz, R. C.; Cavo, M.; Callander, N. S.; Ghobadi, A.; Rodriguez-Otero, P.; Mateos, M. V.; Massaro, M.; Ding, L.; Patel, P.; more...
Blood (2020)

Fulltext@MSK | Save

Molecular characterization of clinical response and relapse in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib and azacitidine

Meeting Abstract

Daigle, S. R.; Choe, S.; DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; more...
Blood (2020)

Fulltext@MSK | Save

SY-1425, a potent and selective RARα agonist, in combination with azacitidine demonstrates a high complete response rate and a rapid onset of response in RARA-positive newly diagnosed unfit acute myeloid leukemia

Meeting Abstract

De Botton, S.; Cluzeau, T.; Vigil, C. E.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
Blood (2020)

Fulltext@MSK | Save